spacer
home > ict > winter 2019 > the evolution of environmental monitoring
PUBLICATIONS
International Clinical Trials

The Evolution of Environmental Monitoring

Clinical trials are a complex undertaking and a huge investment for the sponsor, taking a significant amount of time to complete and to produce a marketable drug. Added complexity comes from the inherently global nature of recent clinical trials which are spreading operations over multiple nations, sites, and premises. Ensuring sufficient enrolment numbers and monitoring activities on multiple sites and suchlike justifiably take up a major portion of sponsor and investigator focus.

A Complicated Process

With the vast amount of analytical activities in a clinical study, it is easy to forget that even in national – and more so, in international studies – logistics complexity is a major concern. However, while logistics is a support function for the overall trial operation, it also needs planning to function efficiently.

In a drug trial, ensuring that the investigational medicinal products (IMPs) reach the site in good condition and that samples travel from collection points to laboratories in correct environments is paramount. With lab specialisation requiring long transportation distances and the parallel supply chains of international, regional, and local hubs often working without visibility to each other, guaranteeing the integrity of the supply is not always easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Jukkapekka ‘JP’ Asikainen is the founder and CEO at Sensire. He is a leading expert on the cold supply chain and an accomplished innovator of marketleading wireless monitoring solutions for pharma logistics, healthcare services, and processing and manufacturing operations. JP is a highly successful serial entrepreneur and has over 30 years’ experience in executive management, marketing and sales. As a longtime specialist on environmental monitoring systems, JP is exceedingly experienced at providing customers with real-life solutions to real-world challenges.

Ossi Laakkonen is Technical Director at Sensire. He is an expert in cold supply chain technology design and accomplished in designing robust and comprehensive environmental monitoring systems for a wide variety of applications. Ossi’s speciality is in the field of IoT and he has over 10 years of experience with working on wireless sensor network research and development. He also holds several groundbreaking patents on these technologies.
spacer
Jukkapekka ‘JP’ Asikainen
spacer
spacer
spacer
Ossi Laakkonen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement